These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
331 related articles for article (PubMed ID: 31101647)
1. A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. Mato AR; Roeker LE; Eyre TA; Nabhan C; Lamanna N; Hill BT; Brander DM; Barr PM; Lansigan F; Cheson BD; Singavi AK; Yazdy MS; Shah NN; Allan JN; Bhavsar EB; Rhodes J; Kennard K; Schuster SJ; Williams AM; Skarbnik AP; Goy AH; Goodfriend JM; Dorsey C; Coombs CC; Tuncer H; Ujjani CS; Jacobs R; Winter AM; Pagel JM; Bailey N; Schuh A; Shadman M; Sitlinger A; Weissbrot H; Muralikrishnan S; Zelenetz A; Kirkwood AA; Fox CP Blood Adv; 2019 May; 3(10):1568-1573. PubMed ID: 31101647 [TBL] [Abstract][Full Text] [Related]
2. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705 [TBL] [Abstract][Full Text] [Related]
3. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy. Freise KJ; Jones AK; Menon RM; Verdugo ME; Humerickhouse RA; Awni WM; Salem AH Hematol Oncol; 2017 Dec; 35(4):679-684. PubMed ID: 27982454 [TBL] [Abstract][Full Text] [Related]
4. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474 [TBL] [Abstract][Full Text] [Related]
5. Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort. Bouclet F; Calleja A; Dilhuydy MS; Véronèse L; Pereira B; Amorim S; Cymbalista F; Herbaux C; de Guibert S; Roos-Weil D; Hivert B; Aurran T; Dupuis J; Blouet A; Tchernonog E; Laribi K; Dmytruck N; Morel P; Michallet AS; Dartigeas C; Tournilhac O; Nguyen-Khac F; Delmer A; Feugier P; Ysebaert L; Guièze R Ann Hematol; 2021 Apr; 100(4):987-993. PubMed ID: 33495922 [TBL] [Abstract][Full Text] [Related]
7. Venetoclax alone or in combination with other regimens treatment achieve deep and sustained remission of relapsed/refractory chronic lymphocytic leukemia: a meta-analysis. Tang X; Zou W; Peng P; Bai Y Clin Exp Med; 2022 May; 22(2):161-171. PubMed ID: 34224006 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis. Eyre TA; Kirkwood AA; Gohill S; Follows G; Walewska R; Walter H; Cross M; Forconi F; Shah N; Chasty R; Hart A; Broom A; Marr H; Patten PEM; Dann A; Arumainathan A; Munir T; Shankara P; Bloor A; Johnston R; Orchard K; Schuh AH; Fox CP; Br J Haematol; 2019 May; 185(4):656-669. PubMed ID: 30768675 [TBL] [Abstract][Full Text] [Related]
9. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States. Chatterjee A; Shapouri S; Manzoor BS; Ravelo A; Sail K; Qendri V; van de Wetering G; Davids MS J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110 [No Abstract] [Full Text] [Related]
11. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. Lin VS; Lew TE; Handunnetti SM; Blombery P; Nguyen T; Westerman DA; Kuss BJ; Tam CS; Roberts AW; Seymour JF; Anderson MA Blood; 2020 Jun; 135(25):2266-2270. PubMed ID: 32244251 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Roberts AW; Ma S; Kipps TJ; Coutre SE; Davids MS; Eichhorst B; Hallek M; Byrd JC; Humphrey K; Zhou L; Chyla B; Nielsen J; Potluri J; Kim SY; Verdugo M; Stilgenbauer S; Wierda WG; Seymour JF Blood; 2019 Jul; 134(2):111-122. PubMed ID: 31023700 [TBL] [Abstract][Full Text] [Related]
13. Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Lei MM; Sorial MN; Lou U; Yu M; Medrano A; Ford J; Nemec RA; Abramson JS; Soumerai JD Leuk Lymphoma; 2024 May; 65(5):653-659. PubMed ID: 38293753 [TBL] [Abstract][Full Text] [Related]
14. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. Wierda WG; Allan JN; Siddiqi T; Kipps TJ; Opat S; Tedeschi A; Badoux XC; Kuss BJ; Jackson S; Moreno C; Jacobs R; Pagel JM; Flinn I; Pak Y; Zhou C; Szafer-Glusman E; Ninomoto J; Dean JP; James DF; Ghia P; Tam CS J Clin Oncol; 2021 Dec; 39(34):3853-3865. PubMed ID: 34618601 [TBL] [Abstract][Full Text] [Related]
15. Is there a role for anti-CD20 antibodies in CLL? Shah HR; Stephens DM Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):68-75. PubMed ID: 34889417 [TBL] [Abstract][Full Text] [Related]
16. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. Seymour JF; Kipps TJ; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Gerecitano J; Robak T; De la Serna J; Jaeger U; Cartron G; Montillo M; Humerickhouse R; Punnoose EA; Li Y; Boyer M; Humphrey K; Mobasher M; Kater AP N Engl J Med; 2018 Mar; 378(12):1107-1120. PubMed ID: 29562156 [TBL] [Abstract][Full Text] [Related]
17. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635 [TBL] [Abstract][Full Text] [Related]